119 related articles for article (PubMed ID: 38430807)
1. Siglec9 + tumor-associated macrophages predict prognosis and therapeutic vulnerability in patients with colon cancer.
Chang J; Feng Q; Mao Y; Zhang Z; Xu Y; Chen Y; Zheng P; Lin S; Shen F; Zhang Z; Zhang Z; He G; Xu J; Wei Y
Int Immunopharmacol; 2024 Mar; 130():111771. PubMed ID: 38430807
[TBL] [Abstract][Full Text] [Related]
2. LINC01004-SPI1 axis-activated SIGLEC9 in tumor-associated macrophages induces radioresistance and the formation of immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma.
Zhao F; Tian H; Wang Y; Zhang J; Liu F; Fu L
Cancer Immunol Immunother; 2023 Jun; 72(6):1835-1851. PubMed ID: 36688997
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer.
Xu Y; Zeng H; Jin K; Liu Z; Zhu Y; Xu L; Wang Z; Chang Y; Xu J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338085
[TBL] [Abstract][Full Text] [Related]
4. Poor clinical outcomes and immunoevasive contexture in SIRPα
Xu Z; Zeng H; Liu Z; Jin K; Chang Y; Wang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Mar; 40(3):109.e11-109.e20. PubMed ID: 34600802
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response.
Qi Y; Chang Y; Wang Z; Chen L; Kong Y; Zhang P; Liu Z; Zhou Q; Chen Y; Wang J; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Y; Xu J; Zhang W
Cancer Immunol Immunother; 2019 Dec; 68(12):2067-2080. PubMed ID: 31720813
[TBL] [Abstract][Full Text] [Related]
6. Poor Clinical Outcomes and Immunoevasive Contexture in Intratumoral IL-10-Producing Macrophages Enriched Gastric Cancer Patients.
Zhang H; Li R; Cao Y; Gu Y; Lin C; Liu X; Lv K; He X; Fang H; Jin K; Fei Y; Chen Y; Wang J; Liu H; Li H; Zhang H; He H; Zhang W
Ann Surg; 2022 Apr; 275(4):e626-e635. PubMed ID: 32541216
[TBL] [Abstract][Full Text] [Related]
7. CXCR6+ Tumor-Associated Macrophages Identify Immunosuppressive Colon Cancer Patients with Poor Prognosis but Favorable Response to Adjuvant Chemotherapy.
Chang J; Lin S; Mao Y; Xu Y; Zhang Z; Wu Q; Chen Y; Wei Y; Feng Q; Xu J
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230570
[TBL] [Abstract][Full Text] [Related]
8. Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer.
Sun M; Zeng H; Jin K; Liu Z; Hu B; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
Cancer Immunol Immunother; 2022 Jun; 71(6):1497-1506. PubMed ID: 34716763
[TBL] [Abstract][Full Text] [Related]
9. Siglec-9
Wang Y; He M; Zhang C; Cao K; Zhang G; Yang M; Huang Y; Jiang W; Liu H
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37709296
[TBL] [Abstract][Full Text] [Related]
10. FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity.
Dong K; Chen W; Pan X; Wang H; Sun Y; Qian C; Chen W; Wang C; Yang F; Cui X
BMC Cancer; 2022 Feb; 22(1):140. PubMed ID: 35120484
[TBL] [Abstract][Full Text] [Related]
11. Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment.
Lv J; Jiang Z; Yuan J; Zhuang M; Guan X; Liu H; Yin Y; Ma Y; Liu Z; Wang H; Wang X
Front Immunol; 2023; 14():1093716. PubMed ID: 37006239
[TBL] [Abstract][Full Text] [Related]
12. Multi-Omics Analysis Showed the Clinical Value of Gene Signatures of C1QC
Li X; Zhang Q; Chen G; Luo D
Front Immunol; 2021; 12():694801. PubMed ID: 34295336
[TBL] [Abstract][Full Text] [Related]
13. Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer.
Lv K; Sun M; Fang H; Wang J; Lin C; Liu H; Zhang H; Li H; He H; Gu Y; Li R; Shao F; Xu J
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935567
[TBL] [Abstract][Full Text] [Related]
14. Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes.
Yang Q; Zhang H; Wei T; Lin A; Sun Y; Luo P; Zhang J
Front Immunol; 2021; 12():756722. PubMed ID: 34804043
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated Macrophages as Prognostic and Predictive Biomarkers for Postoperative Adjuvant Chemotherapy in Patients with Stage II Colon Cancer.
Feng Q; Chang W; Mao Y; He G; Zheng P; Tang W; Wei Y; Ren L; Zhu D; Ji M; Tu Y; Qin X; Xu J
Clin Cancer Res; 2019 Jul; 25(13):3896-3907. PubMed ID: 30988081
[TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
Clin Transl Oncol; 2021 Dec; 23(12):2513-2525. PubMed ID: 34089486
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses.
Zeng H; Liu Z; Wang Z; Zhou Q; Qi Y; Chen Y; Chen L; Zhang P; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
Int J Cancer; 2020 Jan; 146(2):542-552. PubMed ID: 31584197
[TBL] [Abstract][Full Text] [Related]
18. High Expression Levels of SIGLEC9 Indicate Poor Outcomes of Glioma and Correlate With Immune Cell Infiltration.
Xu H; Feng Y; Kong W; Wang H; Feng Y; Zhen J; Tian L; Yuan K
Front Oncol; 2022; 12():878849. PubMed ID: 35756603
[TBL] [Abstract][Full Text] [Related]
19. Blockade of DC-SIGN
Hu B; Wang Z; Zeng H; Qi Y; Chen Y; Wang T; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
Cancer Res; 2020 Apr; 80(8):1707-1719. PubMed ID: 32060149
[TBL] [Abstract][Full Text] [Related]
20. M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer.
JiaWei Z; ChunXia D; CunDong L; Yang L; JianKun Y; HaiFeng D; Cheng Y; ZhiPeng H; HongYi W; DeYing L; ZhiJian L; Xiao X; QiZhao Z; KangYi X; WenBing G; Ming X; JunHao Z; JiMing B; ShanChao Z; MingKun C
Ann Med; 2021 Dec; 53(1):730-740. PubMed ID: 34032524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
